Prospective, randomized, double-blind, active-controlled, multicenter trial of bivalirudin and un-fractionated heparin in patients undergoing percutaneous coronary interventions. ISAR-REACT-3

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bivalirudin (Primary) ; Heparin
Indications Angina pectoris; Cardiovascular disorders; Coronary artery disease; Coronary disorders; Coronary thrombosis; Thrombosis; Unstable angina pectoris
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Acronyms ISAR-REACT 3

11 Feb 2010 Results published in European Heart Journal.
11 Feb 2010 Primary endpoint 'Death rate' has not been met.
11 Feb 2010 Primary endpoint 'Myocardial infarction event rate' has not been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com